Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on October 6, 2009
Japanese Journal of Clinical Oncology 2009 39(11):745-750; doi:10.1093/jjco/hyp122
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/11/745    most recent
hyp122v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miwa, S.
Right arrow Articles by Namiki, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miwa, S.
Right arrow Articles by Namiki, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

A Case of Bone, Lung, Pleural and Liver Metastases from Renal Cell Carcinoma Which Responded Remarkably Well to Zoledronic Acid Monotherapy

Sotaro Miwa, Atsushi Mizokami, Hiroyuki Konaka, Kouji Izumi, Takahiro Nohara and Mikio Namiki

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

For reprints and all correspondence: Atsushi Mizokami, Department of Integrative Cancer Therapy and Urology, 13-1 Takara-machi, Kanazawa City 920-8640, Japan. E-mail address: mizokami{at}med.kanazawa-u.ac.jp

Received January 29, 2009; accepted August 25, 2009

Herein, we report a rare case in which bisphosphonate zoledronic acid (ZA) effectively treated not only multiple bone metastases but also lung, pleural and liver metastases from renal cell carcinoma (RCC). Recently, ZA is used to treat skeletal-related events (SREs) such as bone pain caused by bone metastasis from many kinds of cancer. The patient in the present report had multiple bone metastases from RCC. Remarkable improvement of the bone metastasis was observed following treatment with ZA at a dosage of 4 mg administered once every 4 weeks. Moreover, lung, pleural and liver metastases also diminished markedly in size in response to the treatment. The metastases have shown no progression for 20 months since starting the ZA treatment. We believe that the present report is the first of its kind announcing that ZA monotherapy has been effective for lung, pleural and liver metastases from RCC.

Key Words: renal cell carcinoma • lung metastasis • pleural metastasis • bone metastasis • zoledronic acid


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.